Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against enterobacteriaceae isolates producing verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7145-7147

  Ghazi, Islam M ^a   Crandon, Jared L ^a   Lesho, Emil P ^b   McGann, Patrick ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,8 DIHYDROXYADENINE; BACTERIAL ENZYME; CEFEPIME; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; UNCLASSIFIED DRUG; VERONA INTEGRON ENCODED METALLO BETA LACTAMASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER FREUNDII; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INFUSION; DRUG MEGADOSE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYME SYNTHESIS; GENETIC VARIABILITY; INTEGRON; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THIGH; WILD TYPE; ANIMAL; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; LEVOFLOXACIN; MICE; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS; THIGH;

EID: 84946219821     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00794-15     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention (CDC). 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:165-170.
2. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306-325. http://dx.doi.org/10.1128/CMR.18.2.306-325.2005.
3. Wiskirchen DE, Crandon JL, Nicolau DP 2013. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 41:582-585. http://dx.doi.org/10.1016/j.ijantimicag.2013.02.015.
4. Wiskirchen DE, Nordmann P, Crandon J.L., Nicolau DP. 2014. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemaseinamurine infection model. Antimicrob Agents Chemother 58:1678-1683. http://dx.doi.org/10.1128/AAC.01947-13.
5. Hagihara M, Crandon JL, Urban C, Nicolau DP 2013. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs. J Antimicrob Chemother 68:1616-1618. http://dx.doi.org/10.1093/jac/dkt056.
6. Choi KH, Kumar A, Schweizer HP 2006. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J Microbiol Methods 64:391-397. http://dx.doi.org/10.1016/j.mimet.2005.06.001.
7. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI publication M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Andes D, Craig WA 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 42:2375-2379.
9. Onyeji CO, Bui KQ, Owens R.C., Nicolau SP, Quintiliani R, Nightingale CH. 1999. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents 12:107-114. http://dx.doi.org/10.1016/S0924-8579(98)00087-9.
10. DeRyke CA, Banevicius MA, Fan H.W., Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 4:1481-1486.
11. Crandon JL, Nicolau DP 2015. In vivo activity of humanized cefepime and cefepime/AAI101 against multi-drug resistant Gram-negative Enter-obacteriaceae. Antimicrob Agents Chemother 59:2688-2694. http://dx.doi.org/10.1128/AAC.00033-15.
12. Ambrose PG, Bhavnani SM, Rubino C.M., Louie A., Gumbo T, Forrest A, Drusano GL 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86.
13. Rupp ME, Fey PD 2003. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63:353-365. http://dx.doi.org/10.2165/00003495-200363040-00002.
14. Queenan AM, Shang W, Flamm R., Bush K. 2010. Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 54:565-569. http://dx.doi.org/10.1128/AAC.01004-09.
15. Zhang Y, Jiang X, Wang Y., Li G, Tian Y, Liu H., Ai F, Ma Y, Wang B., Ruan F, Rajakumar K. 2014. Contribution of β-lactamases and porin proteins OmpK35 and OmpK36 to carbapenem resistance in clinical isolates of KPC-2-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 58:1214-1217. http://dx.doi.org/10.1128/AAC.02045-12.
16. MacVane SH, Crandon JL, Nichols W.W., Nicolau DP. 2014. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 58:7007-7009. http://dx.doi.org/10.1128/AAC.02662-14.
17. Wiskirchen DE, Nordmann P, Crandon J.L., Nicolau DP. 2014. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother 58:1671-1677. http://dx.doi.org/10.1128/AAC.01946-13.
18. Daikos GL, Petrikkos P, Psichogiou M., Kosmidis C, Vryonis E, Skoutelis A., Georgousi K, Tzouvelekis LS, Tassios P.T., Bamia C., Petrikkos G. 2009. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 53:1868-1873. http://dx.doi.org/10.1128/AAC.00782-08.
19. Souli M, Kontopidou FV, Papadomichelakis E, Galani I., Armaganidis A, Giamarellou H. 2008. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek university hospital. Clin Infect Dis 46:847-854. http://dx.doi.org/10.1086/528719.